[New treatments in erectile dysfunction].
Palma-Aguirre
J A
JA
Unidad de Investigación Médica en Farmacología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México, D.F.
D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D000527:Alprostadil / Q000493:pharmacokinetics / Q000627:therapeutic use; D000075202:Contraindications; D004347:Drug Interactions; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010646:Phentolamine / Q000493:pharmacokinetics / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000493:pharmacokinetics / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D000527:Alprostadil; D010646:Phentolamine